发明名称 PEGylated mutated clostridium botulinum toxin
摘要 The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C)n-(tag)m-(X)l— in the direction from the N- to the C-terminal end, wherein C represents a cysteine residue,tag represents any tag andX represents the residue of any naturally occurring amino acid,n represents an integer from 1 to 50,m represents 0 or 1, andl represents 0 or an integer from 1 to 50, and in that (ii) at least one of the cysteine residues in the extension of the chain is coupled to at least one chain of PEG.
申请公布号 US8912140(B2) 申请公布日期 2014.12.16
申请号 US201213624493 申请日期 2012.09.21
申请人 Merz Pharma GmbH & Co. KGaA 发明人 Frevert Jürgen;Specht Volker
分类号 A61K38/00;A61K39/00;C07K1/00;C12N9/96;C07K14/33 主分类号 A61K38/00
代理机构 Parker Highlander PLLC 代理人 Parker Highlander PLLC
主权项 1. A pharmaceutical composition comprising a modified botulinum toxin, the modified botulinum toxin comprising a natural heavy chain and a modified light chain, wherein the light chain comprises at least one and at most 20 amino acid residues occurring naturally at its N-terminus being mutated to a cysteine residue, and at least one chain of PEG coupled to at least one cysteine residue in said 20 amino acid residues at said N-terminus.
地址 Frankfurt Au Main DE